Evidence map›Paper›PMID 40947050›Full record

ArticleContemporary clinical trials2025

TeleHealth Resistance exercise Intervention to preserve dose intensity and Vitality in Elder Breast Cancer Patients (THRIVE 65).

Kathryn H Schmitz, Nathan A Berger, Cynthia Owusu, Cynthia A Thomson, Vernon M Chinchilli, Karen Basen-Engquist, William J Evans, John J Pink, Erica A Schleicher, Chao Cao and 10 more

Abstract readClinical Trial Protocol
PubMed Full text at PMC Publisher
In one paragraph

Article in Contemporary clinical trials, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

20 authors.

Kathryn H SchmitzDivision of Hematology Oncology, University of Pittsburgh School of Medicine, UPMC Hillman Cancer Center, 5051 Centre Ave, Suite 5000, Pittsburgh, PA 15232, USA. Electronic address: schmitzk@upmc.edu.
Nathan A BergerDepartment of Medicine, Division of Hematology and Oncology, Case Western Reserve University, 11100 Euclid Avenue, Cleveland, OH 44106, USA.
Cynthia OwusuDepartment of Medicine, Division of Hematology and Oncology, Case Western Reserve University, 11100 Euclid Avenue, Cleveland, OH 44106, USA.
Cynthia A ThomsonDepartment of Health Promotion Sciences, Mel and Enid Zuckerman College of Public Health, University of Arizona, 1295 N Martin, Tucson, AZ 84724, USA. Electronic address: cthomson@arizona.edu.
Vernon M ChinchilliDepartment of Public Health Sciences, Penn State College of Medicine, 500 University Drive, Hershey, PA 17011, USA. Electronic address: vchinchilli@pennstatehealth.psu.edu.
Karen Basen-EngquistDepartment of Health Disparities, MD Anderson Cancer Center, 1515 Holcombe Blvd, Unit 1440, Houston, TZ 77030, USA. Electronic address: kbasenen@mdanderson.org.
William J EvansDepartment of Nutritional Sciences and Toxicology, University of California at Berkeley, 119 Morgan Hall, Berkeley, CA 94720, USA. Electronic address: William.evans@berkeley.edu.
John J PinkDepartment of Medicine, Division of Hematology and Oncology, Case Western Reserve University, 11100 Euclid Avenue, Cleveland, OH 44106, USA.
Erica A SchleicherDivision of Hematology Oncology, University of Pittsburgh School of Medicine, UPMC Hillman Cancer Center, 5051 Centre Ave, Suite 5000, Pittsburgh, PA 15232, USA. Electronic address: schleichere@upmc.edu.
Chao CaoDepartment of Medical Oncology, Dana Farber Cancer Institute, 450 Brookline Ave, Boston, MA 02215, USA. Electronic address: chao_cao@dfci.harvard.edu.
Shawna E DoerksenDivision of Hematology Oncology, University of Pittsburgh School of Medicine, UPMC Hillman Cancer Center, 5051 Centre Ave, Suite 5000, Pittsburgh, PA 15232, USA. Electronic address: doerksens@upmc.edu.
Jenna D BinderDivision of Hematology Oncology, University of Pittsburgh School of Medicine, UPMC Hillman Cancer Center, 5051 Centre Ave, Suite 5000, Pittsburgh, PA 15232, USA. Electronic address: binderjd@upmc.edu.
Michele D SobolewskiDivision of Hematology Oncology, University of Pittsburgh School of Medicine, UPMC Hillman Cancer Center, 5051 Centre Ave, Suite 5000, Pittsburgh, PA 15232, USA. Electronic address: sobolewskim@upmc.edu.
Anna M TanasijevicDepartment of Medical Oncology, Dana Farber Cancer Institute, 450 Brookline Ave, Boston, MA 02215, USA. Electronic address: anna_tanasijevic@dfci.harvard.edu.
Kaedryn A DiguglielmoDepartment of Medical Oncology, Dana Farber Cancer Institute, 450 Brookline Ave, Boston, MA 02215, USA. Electronic address: Kaedryn_diguglielmo@dfci.harvard.edu.
Truong L NguyenDepartment of Medical Oncology, Dana Farber Cancer Institute, 450 Brookline Ave, Boston, MA 02215, USA. Electronic address: truong_nguyen@dfci.harvard.edu.
Carissa A MillsDepartment of Medicine, Division of Hematology and Oncology, Case Western Reserve University, 11100 Euclid Avenue, Cleveland, OH 44106, USA.
Wendy KempDepartment of Medical Oncology, Dana Farber Cancer Institute, 450 Brookline Ave, Boston, MA 02215, USA. Electronic address: wendy_kemp@dfci.harvard.edu.
Jay B OppenheimDepartment of Medical Oncology, Dana Farber Cancer Institute, 450 Brookline Ave, Boston, MA 02215, USA. Electronic address: Jay_oppenheim@dfci.harvard.edu.
Jennifer A LigibelDepartment of Medical Oncology, Dana Farber Cancer Institute, 450 Brookline Ave, Boston, MA 02215, USA. Electronic address: jennifer_ligibel@dfci.harvard.edu.

Funding

VECTOR CORE FACILITYP30CA047904 · UNIVERSITY OF PITTSBURGH AT PITTSBURGH · 1988 to 2025
$32.4M
TeleHealth Resistance exercise Intervention to preserve dose intensity and Vitality in Elder breast cancer patients (THRIVE)U01CA271277 · UNIVERSITY OF PITTSBURGH AT PITTSBURGH · 2025 to 2025
$1.2M
NCI NIH HHS P30 CA047904NCI NIH HHS U01 CA271277
6 · The paper itself

Abstract

backgroundOlder women with breast cancer are more likely than younger women to experience dose-limiting toxicities with chemotherapy. This leads to dose reduction, treatment discontinuation, and inferior treatment outcomes. Older women are also at higher risk of long-term detrimental impacts of treatment on quality of life and physical function.

aimThe primary aim of the TeleHealth Resistance exercise Intervention to preserve dose intensity and Vitality in Elder breast cancer patients (THRIVE-65) trial is to assess the effects of an exercise and nutrition intervention on chemotherapy relative dose intensity among women aged ≥65 receiving chemotherapy for early-stage breast cancer. METHODS/

designTHRIVE-65 is a 2-arm parallel-group randomized controlled trial. The intervention includes two 30-45 min telehealth delivered resistance exercise sessions weekly, 90 min of unsupervised aerobic exercise weekly, and dietitian-guided high protein intake (1.2 g/kg/day)) delivered throughout the course of chemotherapy. The Health Education and Support control group receives a tablet with supportive care materials. Planned and observed chemotherapy dose and treatment schedule are recorded to assess relative dose intensity. Pre- and post- intervention assessments include patient reported outcomes, a geriatric assessment, dietary and physical activity measures, physical function and body composition.

conclusionsThe THRIVE-65 trial is poised to answer a crucial scientific question: Can exercise and nutrition support improve chemotherapy tolerance among older breast cancer patients? Study results will inform clinical practice related to exercise and nutrition support for this population.

Indexed as

Antineoplastic AgentsBreast NeoplasmsResistance TrainingAgedAged, 80 and overFemaleHumansMulticenter Studies as TopicQuality of LifeRandomized Controlled Trials as TopicTelemedicineAntineoplastic AgentsBreast cancerExerciseNutritionRelative dose intensity

Identifiers

PMID40947050
PMCPMC12965287

What Socratic holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.